Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pyxis Oncology (PYXS) Net Income towards Common Stockholders: 2023-2024

Historic Net Income towards Common Stockholders for Pyxis Oncology (PYXS) over the last 2 years, with Dec 2024 value amounting to -$77.3 million.

  • Pyxis Oncology's Net Income towards Common Stockholders fell 3.77% to -$22.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$100.4 million, marking a year-over-year change of. This contributed to the annual value of -$77.3 million for FY2024, which is 4.66% down from last year.
  • According to the latest figures from FY2024, Pyxis Oncology's Net Income towards Common Stockholders is -$77.3 million, which was down 4.66% from -$73.9 million recorded in FY2023.
  • Over the past 5 years, Pyxis Oncology's Net Income towards Common Stockholders peaked at -$73.9 million during FY2023, and registered a low of -$77.3 million during FY2024.
  • In the last 2 years, Pyxis Oncology's Net Income towards Common Stockholders had a median value of -$75.6 million in 2023 and averaged -$75.6 million.
  • Data for Pyxis Oncology's Net Income towards Common Stockholders shows a maximum YoY declined of 4.66% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Pyxis Oncology's Net Income towards Common Stockholders stood at -$73.9 million in 2023, then declined by 4.66% to -$77.3 million in 2024.